South Africa

Accord started its commercial activities in 2006 with its first marketing authorization from the South African regulatory authority. Accord has rapidly progressed its full fledged commercial marketing activities across South Africa, offering high quality generics in a wide variety of therapeutic areas such as Cardiology, Neurology, Nephrology, Urology, Psychiatry, Diabetology, Pain Management, Oncology and Gastroenterology. Till date, Accord South Africa has successfully leveraged its capabilities within multinational group, to bring affordable and bioequivalent generics with impeccable international credentials to the South African patients and healthcare practitioners. We already have a portfolio of over 26 molecules across multiple therapeutic classes. We are committed to build up this number to compete with the largest product ranges in the sector. Accord has a particular focus on ensuring the safe use of our products, both for patients and medical professionals.

Accord now has a marketing presence nationally through our sales teams and extensive partnering with major wholesalers, retailers and hospital groups. As of 2012, we have expanded our direct offering of chronic medications to state patients at affordable prices and consistent quality. Till date, we have gained over 100 marketing authorizations in South Africa and expect this number to increase significantly over the next few years. The cornerstone of Accord’s offering to the South African market is exceptional quality, affordability and service to healthcare professionals, their patients and supply chain partners.

In the future, the Accord Healthcare is committed to maintaining the highest international standards of quality of generic medication to patients and is deeply invested in contributing to the improvement of medical care for South African patient population across the globe.

For more information, visit (